2K3 Stock Chart & Stats
€16.20
€0.10(0.71%)
At close: 4:00 PM EDT
€16.20
€0.10(0.71%)
Day’s Range― - ―
52-Week Range€9.65 - €19.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€877.39M
Enterprise Value€622.72M
Total Cash (Recent Filing)€145.94M
Total Debt (Recent Filing)€7.17M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Nov 02, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding44,818,577
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)4.83
Price to Sales (P/S)4.27
P/FCF Ratio-94.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.27Price Target Upside37.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.35
Revenue Forecast (FY)€206.68M
Bulls Say, Bears Say
Bulls Say
Revenue And Physician ExpansionDouble-digit revenue growth combined with a broader physician base supports durable adoption of SI-BONE’s procedure-focused portfolio. More active physicians can expand procedure volume, deepen hospital relationships, and improve the company’s ability to compound sales as its commercial territory expands.
High Gross Margins And Improving EBITDAA gross margin near 80% provides meaningful economic room to fund commercial expansion, product development, and infrastructure. The sharp improvement in adjusted EBITDA indicates operating leverage is emerging as revenue scales, although continued execution is needed to convert that progress into GAAP profitability.
Conservative Leverage And LiquidityVery low leverage and substantial liquidity give SI-BONE flexibility to invest in surgical capacity, product launches, and development without relying heavily on debt. This stronger financial foundation also improves resilience while the company works toward sustained profitability and positive free cash flow.
Bears Say
GAAP Losses PersistAlthough losses are narrowing, continued GAAP unprofitability shows that the current revenue base has not yet fully absorbed operating costs and investment spending. Persistent losses can delay internally funded expansion and leave results more sensitive to execution, launch timing, and expense growth.
Free Cash Flow Remains NegativeImproving operating cash flow is encouraging, but negative free cash flow means SI-BONE is not yet consistently self-funding after capital expenditures and investment needs. Planned headquarters and surgical-capacity spending may extend cash-flow variability and constrain flexibility if profitability takes longer to arrive.
Sterile Packaging RecallThe recall introduces operational and regulatory risk because sterile-barrier failures can require product reprocessing, physician coordination, and additional quality oversight. No infections or adverse events were reported, but the event could still affect execution and confidence in the affected product line.
2K3 FAQ
What was SI-Bone Inc’s price range in the past 12 months?
SI-Bone Inc lowest stock price was €9.65 and its highest was €19.00 in the past 12 months.
What is SI-Bone Inc’s market cap?
SI-Bone Inc’s market cap is €877.39M.
When is SI-Bone Inc’s upcoming earnings report date?
SI-Bone Inc’s upcoming earnings report date is Nov 02, 2026 which is in 4 days.
How were SI-Bone Inc’s earnings last quarter?
SI-Bone Inc released its earnings results on Aug 03, 2026. The company reported -€0.081 earnings per share for the quarter, beating the consensus estimate of -€0.134 by €0.053.
Is SI-Bone Inc overvalued?
According to Wall Street analysts SI-Bone Inc’s price is currently Undervalued.
Does SI-Bone Inc pay dividends?
SI-Bone Inc does not currently pay dividends.
What is SI-Bone Inc’s EPS estimate?
SI-Bone Inc’s EPS estimate is -0.11.
How many shares outstanding does SI-Bone Inc have?
SI-Bone Inc has 44,818,577 shares outstanding.
What happened to SI-Bone Inc’s price movement after its last earnings report?
SI-Bone Inc reported an EPS of -€0.081 in its last earnings report, beating expectations of -€0.134. Following the earnings report the stock price went down -4.575%.
Which hedge fund is a major shareholder of SI-Bone Inc?
Currently, no hedge funds are holding shares in DE:2K3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SI-Bone Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€22.27 (37.47% Upside)
€22.27 (37.47% Upside)
Blogger Sentiment
Bullish
DE:2K3 Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth €495.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.25%
12-Months-Change
Fundamentals
Return on Equity
-8.23%
Trailing 12-Months
Asset Growth
7.72%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
SI-Bone Inc
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
2K3 Company Deck
2K3 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong top-line growth, expanding physician adoption, robust gross margins, and meaningful improvement in adjusted EBITDA and cash balances. Management filed a 510(k) for a third breakthrough device, expects phased commercial launch in Q4, and benefited from favorable reimbursement actions (new DRGs and proposed SI joint increases). At the same time, the company remains modestly unprofitable on a GAAP basis, is investing in capacity and R&D which will cause near-term variability in cash flow and depreciation, and is taking a conservative view on near-term guidance due to seasonality and timing of catalysts. Overall, positives (growth, margin strength, reimbursement tailwinds, product pipeline and liquidity) outweigh near-term execution and timing risks.View all DE:2K3 earnings summaries2K3 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€22.27
▲(37.47% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Alphatec Holdings
―
Orthofix Medical
―
Zimmer Biomet Holdings
―
Globus Medical
―
Xtant Medical Holdings
―









